These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15480657)

  • 21. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
    Thomson SA; Sherritt MA; Medveczky J; Elliott SL; Moss DJ; Fernando GJ; Brown LE; Suhrbier A
    J Immunol; 1998 Feb; 160(4):1717-23. PubMed ID: 9469429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
    Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
    Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
    Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
    J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation.
    Kotecha MT; Afghan RK; Vasilikopoulou E; Wilson E; Marsh P; Kast WM; Davies DH; Caparros-Wanderley W
    Vaccine; 2003 Jun; 21(19-20):2506-15. PubMed ID: 12744885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.
    Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD
    J Immunol; 2003 Nov; 171(10):5611-23. PubMed ID: 14607970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
    Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
    Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.
    Sadovnikova E; Zhu X; Collins SM; Zhou J; Vousden K; Crawford L; Beverley P; Stauss HJ
    Int Immunol; 1994 Feb; 6(2):289-96. PubMed ID: 7512375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.
    Pinchuk I; Starcher BC; Livingston B; Tvninnereim A; Wu S; Appella E; Sidney J; Sette A; Wizel B
    J Immunol; 2005 May; 174(9):5729-39. PubMed ID: 15843575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
    Woo WP; Doan T; Herd KA; Netter HJ; Tindle RW
    J Virol; 2006 Apr; 80(8):3975-84. PubMed ID: 16571814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
    Kim MS; Sin JI
    Immunology; 2005 Oct; 116(2):255-66. PubMed ID: 16162274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.
    Liu W; Gao F; Zhao KN; Zhao W; Fernando GJ; Thomas R; Frazer IH
    Virology; 2002 Sep; 301(1):43-52. PubMed ID: 12359445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine.
    Seyed N; Taheri T; Vauchy C; Dosset M; Godet Y; Eslamifar A; Sharifi I; Adotevi O; Borg C; Rohrlich PS; Rafati S
    PLoS One; 2014; 9(10):e108848. PubMed ID: 25310094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach.
    Yao Y; Huang W; Yang X; Sun W; Liu X; Cun W; Ma Y
    Vaccine; 2013 Apr; 31(18):2289-94. PubMed ID: 23499609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
    mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
    Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
    Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
    Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
    Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.
    Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM
    Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.